“There is urgency in learning how to best block the fatal inflammatory response” – Miriam Merad, MD, PhD
Intestinal biopsy showing Coronavirus receptor (ACE2) expression


SARS-CoV-2, which causes COVID-19, affects the host immune system causing hyperinflammation and may lead to severe multi-organ dysfunction and death. Therefore, we are working to understand the mechanisms underlying the immune abnormalities in patients with COVID-19 which will help in the development of new therapeutic strategies against COVID-19.

In a new development, our researchers have identified a unique pattern of immune responses that characterize multisystem inflammatory syndrome in children (MIS-C) and could serve as a biomarker, or reliable indicator that would help diagnose the disease.


The team of scientists at PrIISM are working to identify early predictors of disease severity to guide life-saving immunotherapy interventions and discover new therapeutic strategies. This will have transformative and immediate impact on the course of the pandemic. In parallel to these research efforts, we initiated an institutional effort, the Sinai Immunology Review Project, to evaluate the quality of the research of COVID-19 articles posted on the preprint servers bioRxiv and medRxiv and help advance the most significant findings. We have also launched a collaboration with Nature Reviews Immunology to publish short summaries of preprints of particular interest in a weekly column.